Google_______________

Risk Factors for Liver Fibrosis in Veterans with Chronic Hepatitis

Chronic hepatitis C virus (HCV) infection can lead to advanced liver fibrosis and cirrhosis, usually over a period of 10-40 years.

In an attempt to better understand the risk factors for fibrosis progression in groups with a high prevalence of HCV infection, researchers compared demographic, clinical, and independent variables influencing fibrosis progression in 459 U.S. veterans and 395 non-veterans with chronic hepatitis C; results were reported in the January 2007 Journal of Viral Hepatitis.

Study participants completed a detailed questionnaire concerning medical, social, and occupational issues. Clinical factors associated with progressive liver disease were compared and fibrosis stage was assessed by liver biopsy (available for 168 veterans and 208 non-veterans).

Results

Although the veterans were significantly older and had higher lifetime alcohol consumption than non-veterans, their median fibrosis scores did not differ from those of non-veterans.

By univariate analysis, alanine aminotransferase (ALT) level, necroinflammatory activity, and cryoglobulin positivity were associated with fibrosis in both veterans and non-veterans.

Steatosis (fat accumulation in the liver) was associated with fibrosis only in non-veterans.

By multivariate analysis, necroinflammatory activity was an independent risk factor for fibrosis in both groups.

However, fibrosis in non-veterans was also independently associated with steatosis, significant alcohol consumption, and age.

Conclusion

"Independent risk factors for fibrosis vary among high HCV prevalence groups such as veterans when compared with non-veterans," the researchers concluded. "Understanding specific patient cohort effects is important for determining independent risk factors for disease progression in chronic HCV infection."

02/06/07

Reference
Z Kayali, S Tan, L Shinkunas, and others. Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans. Journal of Viral Hepatitis 14(1): 11-21. January 2007.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron

FDA-approved
Combination
Therapies
for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Index of All
Hepatitis C Articles
by Topic ( A to Z)